Antifibrotic therapies should be considered when patients on immunosuppressant therapy begin to develop either progressive changes pathophysiologically or on imaging that suggest fibrosis are likely to benefit from antifibrotic therapy. These therapies should also be considered when there is a strong suspicion that the patient has a PF-ILD pattern.
Learn more about medication for PF-ILD.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Zab Mosenifar. Fast Five Quiz: Interstitial Lung Disease Progressive Fibrosing Management - Medscape - Feb 01, 2022.